Basecamp Research

Executive Summary

Basecamp Research is a UK-based biotechnology company founded in 2019 that combines artificial intelligence with global biodiversity exploration to discover novel proteins and enzymes. The company's platform maps the planet's biological data, moving beyond known sequences to unlock new solutions for industrial and therapeutic applications. By leveraging a unique dataset of under-explored environments, Basecamp identifies functional proteins with enhanced properties, aiming to replace synthetic chemicals and enable novel therapies. The approach addresses key challenges in protein engineering, such as stability and activity, by tapping into nature's vast repertoire of evolved molecules. With a focus on sustainability and innovation, Basecamp positions itself at the intersection of AI and synthetic biology. Basecamp Research's platform is designed to accelerate the development of bio-products for sectors including pharmaceuticals, agriculture, and materials science. The company's AI models are trained on proprietary metagenomic data from extreme environments, yielding enzymes with superior performance. While still in a private stage with no disclosed funding, the team has demonstrated proof-of-concept through collaborations and academic publications. The market for engineered enzymes and proteins is substantial, driven by demand for green chemistry and precision medicine. As Basecamp scales its discovery engine, it has the potential to become a key partner for industries seeking sustainable alternatives. However, the path to commercialization carries risks typical of early-stage biotech, including technical validation and capital requirements.

Upcoming Catalysts (preview)

• Q1 2027Strategic R&D partnership with a major industrial enzyme user (e.g., BASF, Novozymes)55% success
• Q4 2026Completion of a Series A funding round (target $15-20M)70% success
• Q3 2026Publication of a flagship paper in Nature or Science demonstrating platform capabilities60% success